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Abstract
Background: Bletillae Rhizoma, the tuber of Bletilla striata, has been used in Chinese traditional medicine to treat
infectious diseases. Chemical studies indicated that phenanthrene was one of the most important components of
the herb, with a broad spectrum of antibiotic activity against Gram-positive bacteria. The objective of this study was
to further characterize the antibacterial activity of the phenanthrene fraction from the fibrous root of the
pseudobulb of B. striata.
Methods: The phenanthrene fraction (EF60) from the ethanol extract of fibrous roots of Bletilla striata pseudobulbs
was isolated using polyamide column chromatography. The antibacterial activity of the fraction was evaluated in
vitro using a 96-well microtiter plate and microbroth dilution method. The cytotoxicity of EF60 against mammalian
cells was tested by hemolysis and MTT assays.
Results: EF60 was obtained using alcohol extraction and polyamide column chromatography, with a yield of 14.9 g
per 1 kg of the fibrous roots of B. striata. In vitro tests indicated that EF60 was active against all tested strains of
Staphylococcus aureus, including clinical isolates and methicillin-resistant S. aureus (MRSA). The minimum inhibitory
concentration (MIC) values of EF60 against these pathogens ranged from 8 to 64 μg/mL. Minimum bactericidal
concentration tests demonstrated that EF60 was bactericidal against S. aureus 3304 and ATCC 29213 and was
bacteriostatic against S. aureus 3211, ATCC 25923, and ATCC 43300. Consistently, the time-kill assay indicated that
EF60 could completely kill S. aureus ATCC 29213 at 2× the MIC within 3 h but could kill less than two logarithmic
units of ATCC 43300, even at 4× the MIC within 24 h. The postantibiotic effects (PAE) of EF60 (4× MIC) against
strains 29213 and 43300 were 2.0 and 0.38 h, respectively. Further studies indicated that EF60 (160 μg/mL) showed
no cytotoxicity against human erythrocytes, and was minimally toxic to Human Umbilical Vein Endothelial Cells
with an IC50 of 75 μg/mL.
Conclusions: Our studies indicated that EF60 is worthy of further investigation as a potential phytotherapeutic
agent for treating infections caused by S. aureus and MRSA.
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Background
With the widespread use of antibiotics, antimicrobial re-
sistance has become a major medical and public health
problem [1–3]. Of particular concern is methicillin-
resistant Staphylococcus aureus (MRSA), which has dis-
seminated throughout the world and is a global human
health problem due to infections in both hospitals and
the community [4, 5]. Glycopeptides are the gold stand-
ard to treat MRSA infections, but vancomycin- and
teicoplanin-resistant bacteria have also emerged [6–8].
There is therefore an urgent need for new strategies to
treat the infections caused by antibiotic-resistant patho-
gens. The discovery and development of antibacterial
natural products, which are becoming increasingly
popular among consumers, are an alternative method
for controlling these diseases [9, 10].
Bletillae Rhizoma, the pseudobulbs of Bletilla striata
(Reichb. f.), has been used in Chinese traditional medi-
cine to treat pneumorrhagia and pneumonophthisis [11].
It is also frequently applied for curing skin cracks, ab-
scesses, and burns when combined with other herbal
medicine. Previous investigations on the constituents of
Bletillae Rhizoma have revealed the presence of mono-
meric phenanthrene, dimeric phenanthrenes, and their
derivatives, which contain a potent antibacterial activity
against Gram-positive bacteria [12–14]. It is worth not-
ing that phenanthrenes are a rather uncommon class of
aromatic metabolites that have mainly been found in the
Orchidaceae family [14]. Although a large number of
phenanthrenes have been isolated from Bletillae
Rhizoma and have been demonstrated to possess anti-
microbial activities, further pharmacological studies of
these compounds are limited due to low content of
phenanthrenes in the pseudobulbs of B. striata.
The fibrous roots of the pseudobulbs of B. striata are usu-
ally discarded during its processing and commercialization,
which represents a waste of natural resources. Our re-
cent study indicated that the chemical composition of
fibrous roots is similar to that of B. striata pseudo-
bulbs; however, the total phenolic content in the former
is higher than that in the latter [15]. Further study
showed that the fibrous part of B. striata is a rich
source of phenanthrene compounds, and six phenan-
threnes, including four new biphenanthrenes contain-
ing antibacterial activity, were isolated from a 95%
ethanol extract [16]. To date, 34 phenanthrene com-
pounds isolated from B. striata have been extensively
described [12–14, 16–18]. However, there was a pre-
dominant tendency to publish the isolation and activity
screening of phenanthrenes in the past years. Little in-
formation is available on the antimicrobial activity
more in depth of this kind of compounds, regardless of
monomer or mixture. Thus, the aim of this study was
to isolate and characterize further the antimicrobial




S. aureus ATCC 25923, S. aureus ATCC 29213, S. aureus
ATCC 43300, E. coli ATCC 35218, and P. aeruginosa
ATCC 27853 were purchased from the American Type
Culture Collection. Bacillus subtilis 168 was a gift
from Mei-Ya Li (Zhejiang Chinese Medical University,
Hangzhou, China). Clinical isolates were obtained from pa-
tients at the Shaoxing Central Hospital, Shaoxing, China.
Preparation of the phenanthrene fraction
The rhizomes of B. striata were collected from Tuankou
Town, Zhejiang Province, People’s Republic of China,
and authenticated by Prof. ZS Ding (one of the authors).
A voucher specimen was deposited in Zhejiang Chinese
Medical University with specimen number BS-2012-I.
The air-dried and powdered fibrous roots (1.0 kg) were
extracted with 15 L of 95% ethanol under reflux, three
times (each time, 60 min). The extract was concentrated
under reduced pressure and yielded 94 g of crude ethanol
extract. The ethanol extract was loaded onto a polyamide
resin column and washed with distilled water, followed by
elution with 20, 40, 60, 80, and 95% (v/v) ethanol. Each
fraction was collected and tested for antibacterial activity
using the agar diffusion method [19]. The tests were re-
peated three times to ensure reliability. The active fraction
(EF60) eluted with 60% ethanol in water were dried in a
vacuum and analyzed using a Dionex Ultimate 3000
high-performance liquid chromatography (HPLC) System
(Thermo Fisher Scientific, Waltham, USA) with a diode-
array ultraviolet/visible (UV–VIS) detector. HPLC was
performed using a Venusil XBP C18 (5 μm, 250 ×
4.6 mm) column eluted with a gradient mixture of
acetonitrile in water containing 0.1% formic acid,
from 5 to 95% in 60 min.
Determination of MIC and MBC
The minimum inhibitory concentration (MIC) was de-
termined using a 96-well microtiter plate and the micro-
broth dilution method as previously reported [20, 21].
Briefly, bacteria were seeded at 2 × 105 cells per well
(200 μL) in a 96-well plate containing Mueller–Hinton
(MH) broth (0.2% meat extracts, 1.75% acid digest of ca-
sein, and 0.15% starch) with varying concentrations of
each test sample. Vancomycin and berberine were used
as positive controls. Dimethyl sulfoxide (DMSO; 10 μL)
and MH broth alone were used as negative controls.
The MIC was defined as the lowest concentration that
completely prevented visible growth after incubation at
37 °C for 18–20 h.
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The minimum bactericidal concentration (MBC) was
determined from tubes showing complete inhibition. A
MH agar plate was seeded with 100-μL aliquots from clear
tubes and incubated for 24 h at 37 °C. The MBC was de-
fined as the lowest compound concentration resulting
in a ≥3-log reduction in the number of CFU [22].
Time-kill curves
The time-kill kinetics of antimicrobial agent against S.
aureus ATCC 29213 and ATCC 43300 were determined
[23, 24]. A logarithmic-phase broth culture of S. aureus
was diluted in MH broth to a final count of approxi-
mately 5 × 105 CFU/mL; next the antimicrobial agent
was added to the broth culture to yield concentrations
of 1 ×, 2 ×, and 4 × the MIC. An equivalent volume of
DMSO was added to the vehicle control tube. The culture
was incubated at 37 °C with shaking for 24 h. Surviving
clones in each culture were determined by withdrawing
samples at various time points and plating the appropriate
serial dilutions onto MH agar plates.
Effect of pH and inoculum size
The effect of changes in the pH of the medium and the
inoculum size on the MIC of antimicrobial agent against
S. aureus ATCC 29213 and ATCC 43300 were assessed
[25]. The MIC was determined using the microbroth di-
lution method as described above. Inoculum size was
remained constant in the MH broth (1 × 105 CFU/mL)
when the pH of the culture was adjusted to 5.0, 7.2, and
9.0 with either HCl or NaOH. In contrast, the pH value
of the MH broth remained at 7.2, while the inoculum
size changed to 103, 105, and 107 CFU/mL. To prevent
interference from the high inoculum concentration on
the MIC, the MBCs were used to confirm the MICs. All
experiments were conducted in triplicate.
Postantibiotic effect
The Postantibiotic effect (PAE) of EF60 against S. aureus
ATCC 29213 and ATCC 43300 was determined using
MH broth. The sterilized antimicrobial agent was added
to a logarithmic-phase broth culture of approximately
105 CFU/mL to give concentrations equivalent to 1×,
2×, and 4× the MIC. In addition, a culture containing
5% DMSO was used as the growth control. Following
1 h of exposure at 37 °C, the antibiotic concentration
was reduced via a 1,000-fold dilution into prewarmed
MH broth and incubated at 37 °C for 24 h. Viable
counts were measured on antibiotic-free MH broth prior
to exposure and at 1, 2, 4, 6, 8, and 24 h after
neutralization by dilution. The PAE was then measured
according to the method previously described [26].
Cytotoxicity assay
The cytotoxicity of EF60 against human red blood cells
was assayed as previously described [27]. Human blood
samples were obtained from normal volunteers.
Hemolysis of red blood cells was induced by the addition
of EF60, and cells were incubated for 2 h at 37 °C in
0.9% saline. The cytotoxicity of EF60 versus Human
Umbilical Vein Endothelial Cells (HUVEC) was tested
using a 48-h continuous 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assays as previ-
ously described [28].
Statistical analysis
Statistical analyses were performed using SPSS software
(Statistical Software Package for Windows, version 19).
The PAEs were expressed as the mean ± standard devi-
ation, and differences are considered to be statistically
significant at P < 0.05.
Results
Isolation of phenanthrene fractions from the fibrous roots
of B. striata
To obtain phenanthrene fractions, ethanol extract from
the fibrous roots of B. striata was loaded onto a poly-
amide resin column and eluted using step-gradient etha-
nol in water to generate five fractions, namely EF20,
EF40, EF60, EF80, and EF95. Phenanthrenes were ana-
lyzed by analytical HPLC and identified by congruent re-
tention times and UV–VIS spectrum, and EF60 was
found to be rich in phenanthrenes (Additional file 1:
Figure S1, Table S1, and Figure S2). Further study indi-
cated that EF60 had good activity against S. aureus
(Table 1). Thus, in the current work, subsequent efforts
were focused on the characterization of this active frac-
tion. EF60 was produced as described in the Methods
section with a yield of 14.9 g per 1 kg of fibrous root.
Antibacterial activity of EF60
The antimicrobial activities of EF60 were evaluated against
16 Gram-positive and 2 Gram-negative bacteria strains. As
expected, EF60 was active against all the Gram-positive
bacteria, with the MICs ranging from 8 to 64 μg/mL
(Table 2). However, EF60 was not active against each of the
Gram-negative bacteria (MIC > 128 μg/mL). Although ber-
berine, a famous natural product from Chinese herbs, had
antimicrobial activity against both Gram-positive and
Gram-negative bacteria [29], its MIC against most of the
strains examined was found to be >64 μg/mL (Table 2). It
is worth noting that clinical isolates of S. aureus and
MRSA ATCC 43300 were also sensitive to EF60.
To evaluate the bactericidal behavior of EF60, the
MBC was determined for the three standard strains and
the two clinical isolates of S. aureus. The control agent,
vancomycin, yielded MBC/MIC ratios of 1–2 against all of
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the strains tested (Table 3), indicative of bactericidal anti-
staphylococcal behavior. Interestingly, EF60 exhibited
MBC/MIC ratios of 1–2 against ATCC 21923 and clinical
isolate 3304, but it yielded MBC/MIC ratios >8 against
ATCC 25923, ATCC 43300, and clinical isolate 3211
(Table 3). In accordance with the standards of the Clinical
and Laboratory Standards Institute [30], an MBC/MIC ra-
tio of 1–2 is indicative of bactericidal behavior, while a
corresponding MBC/MIC ratio ≥8 is indicative of bac-
teriostatic behavior. Thus, EF60 is bactericidal against S.
aureus 3304 and ATCC 29213 and bacteriostatic against
S. aureus 3211, ATCC 25923, and ATCC 43300. Similarly,
berberine was bacteriostatic against S. aureus ATCC
25923 and ATCC 29213 and bactericidal against S. aureus
3211, 3304, and ATCC 43300.
To further examine the bactericidal/bacteriostatic
activities of EF60 against S. aureus with regard to
MBC/MIC ratios, killing experiments against ATCC
29213 and 43300 were performed. As shown in Fig. 1,
EF60 produced >3 logs of kill against ATCC 29213 at
concentrations of ≥2 × the MIC. However, less than 2
logarithmic units of killing were observed, even at 4×
the MIC of EF60, against ATCC 43300. This observa-
tion is consistent with the bactericidal/bacteriostatic
behavior revealed by the MBC/MIC analysis described
above. It is worth mentioning that at concentrations
of ≥2× the MIC, the killing kinetics of EF60 against
ATCC 29213 are faster than those of vancomycin.
Table 1 Antimicrobial activity of different polyamide resin elution fractions from Bletilla striata fibrous root ethanol extract
Indicator strain Inhibition zone size (mm diameter)
EF20a EF40a EF60a EF80a EF95a Ampb
Staphylococcus aureus ATCC 25923 NA 12 ± 0.4 21 ± 0.7 NA NA 27 ± 0.6
Escherichia coli ATCC 35218 NA NA NA NA NA 20 ± 0.3
aRelative inhibition zone (mm) at 100 μg per paper disc
bRelative inhibition zone (mm) at 10 μg per paper disc
Amp ampicillin
NA no activity
Table 2 MIC of EF60 against standard strains and clinical
isolates
Indicator strain MIC (μg/mL)a
EF60 Berberine Vancomycin
S. aureus ATCC 25923 32 128 2
S. aureus ATCC 29213 16 64 1
S. aureus ATCC 43300 8 128 2
S. aureus 5021 64 64 1
S. aureus 5022 16 64 1
S. aureus 5023 32 128 1
S. aureus 5024 64 256 2
S. aureus 5025 16 128 1
S. aureus 5026 16 256 1
S. aureus 5027 16 64 1
S. aureus 5028 16 64 1
S. aureus 5029 16 64 1
S. aureus 3211 8 128 1
S. aureus 3304 16 128 1
S. aureus 2798 8 128 1
Bacillus subtilis 168 32 128 0.25
Escherichia coli ATCC 35218 >128 128 —
Pseudomonas aeruginosa ATCC 27853 >128 256 —
MIC minimum inhibitory concentration
a—, not determined
Table 3 The MBC of EF60 against standard strains and clinical
isolates
Strain and compound MIC (μg/mL) MBC (μg/mL) MBC/MIC
S. aureus ATCC 25923
EF60 32 >256 >8
Berberine 128 >512 >4
Vancomycin 2 2 1
S. aureus ATCC 29213
EF60 16 32 2
Berberine 64 >512 >8
Vancomycin 1 2 2
S. aureus ATCC 43300
EF60 8 >128 >8
Berberine 128 128 1
Vancomycin 2 2 1
S. aureus 3211
EF60 8 >128 >16
Berberine 128 256 2
Vancomycin 1 2 2
S. aureus 3304
EF60 16 32 2
Berberine 128 128 1
Vancomycin 1 1 1
MIC minimum inhibitory concentration
MBC minimum bactericidal concentration
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Effect of pH and inoculum size on MICs of EF60
Table 4 summarized the MICs for the two strains of S.
aureus obtained at different pH and inoculum concen-
trations. There was only a twofold increase in the MICs
of EF60 for ATCC 29213 and 43300, from 16 and 8 μg/
mL at pH 5 to 32 and 16 μg/mL at pH 9, respectively.
Similar reduction potency was observed when the inocu-
lum sizes changed from 103 to 107 CFU/mL. Generally,
both the pH and inoculum sizes did not significantly
affect the MICs of EF60 against the two strains of S. aur-
eus under the tested conditions.
Postantibiotic effect
The PAE of EF60 on the reference strains was deter-
mined and is shown in Table 5. A PAE of > 1.5 h was
observed on strain ATCC 29213 for all tested concentra-
tions of EF60, compared with the maximum PAE of
0.38 h for strain 43300 after exposure to 64 μg/mL of
EF60. Although the PAE of EF60 increased with increas-
ing concentrations of the drug, the dose-dependent PAE
on S. aureus from 1 to 4× the MIC of EF60 was not sig-
nificant (P > 0.05).
Cytotoxicity
The cytotoxicity of EF60 against mammalian cells was
tested by hemolysis and MTT assays. No hemolytic
activity was observed against human erythrocytes when
the concentration of EF60 reached 160 μg/mL. At this
concentration, EF60 effectively inhibited the growth of
all of the Gram-positive bacteria tested, including MRSA.
However, EF60 was minimally toxic to HUVEC, with an
IC50 of 75 μg/mL, indicating a different cytotoxicity
against cell lines derived from diverse tissues. Future stud-
ies with additional human cell lines will be done to evalu-
ate the toxicity of EF60.
Discussion
In this study, a plant fraction (EF60) from the ethanol
extract of fibrous roots of B. striata pseudobulbs was iso-
lated and characterized. EF60 was eluted from a poly-
amide resin column with 60% ethanol and found to be
rich in phenanthrenes. Antimicrobial activity tests demon-
strated that EF60 had good activity against Gram-positive
bacteria, including S. aureus clinical isolates and MRSA.
Interestingly, the MICs of EF60 against all tested S. aureus
strains were 8–64 μg/mL and lower than those of berber-
ine (Table 2), which is a famous natural antibiotic in
China. On the basis of the MIC values, which are below
100 μg/mL for the fraction against Gram-positive bacteria,
EF60 is regarded as a significantly active antibacterial
agent and deserve our full attention [31, 32].
Many antibiotics used in clinical, such as penicillin,
vancomycin, and daptomycin, exhibit fast and bacteri-
cidal effects. Some, such as erythromycin and tigecyc-
line, however, are bacteriostatic rather than bactericidal.
To evaluate the bactericidal behavior of EF60, the MBC
Fig. 1 Time-kill curves for Staphylococcus aureus ATCC 29213 and 43300. Each data point reflects the average of two independent measurements.
The curves are viable cell concentrations plotted against time. Open circles, nondrug control; closed squares, 1× MIC of EF60; closed triangles, 2×
MIC of EF60; closed circles, 4× MIC of EF60; asterisk, 4× MIC of vancomycin. MIC, minimum inhibitory concentration
Table 4 The effect of changes in the pH medium and the
inoculum size on EF60 activity
Influence factor MIC (μg/mL)
S. aureus ATCC 29213 S. aureus ATCC 43300








MIC minimum inhibitory concentration
Table 5 PAE of EF60 against Staphylococcus aureus strainsa
Drug concentration
in μg/mL
PAE (h) mean ± SD
S. aureus ATCC 29213 S. aureus ATCC 43300
16 (1× MIC) 1.53 ± 0.08 0.28 ± 0.04
32 (2× MIC) 1.87 ± 0.02 0.30 ± 0.06
64 (4× MIC) 2.00 ± 0.05 0.38 ± 0.06
aApproximately 105 CFU/mL was exposed to different concentrations of EF60
for 1 h
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was determined for five S. aureus strains. As shown in
Table 3, against 3 of these strains EF60 showed only
bacteriostatic activities. With the other 2 strains, bacteri-
cidal activities of EF60 were observed. Similar phenom-
ena were also observed for berberine and in other
studies [33]. The bactericidal/bacteriostatic behavior of
EF60 was confirmed by time-kill assays (Fig. 1).
It was reported that the pH of culture medium or in-
oculum size had an effect on the antibacterial activities
of some antibiotics [25, 31]. For example, amifloxacin
was more active against Staphylococcus saprophyticus at
pH 6.0 than at 7.0 [25], while the oil of Cedrus deudora
had most active at pH 9 [31]. In the present study, varia-
tions in the pH of the medium or inoculum density had
no significant effect on the activity of EF60 (Table 4), in-
dicated this plant fraction had a high stability when sus-
ceptibility test conditions were modified.
PAE is the phenomenon of suppression of bacterial
growth after a short exposure to antimicrobial agents
[26, 34]. It is an important parameter of antibiotic ac-
tion, and provides reference data for designing antibiotic
dosage regimens. Previous studies indicated that many
test antibiotics had a persistent inhibition of bacterial
growth after a brief antimicrobial exposure to microor-
ganisms [35–37], while some drugs had insignificant
PAE [34]. Our study showed that the PAE was related
with both the concentration of EF60 and test strains: for
example, the PAEs for Strain ATCC 29213 were 1.53 h
after exposure to 16 μg/mL and 2.0 h after exposure to
64 μg/mL, but the PAE for Strain ATCC 43300 was
0.38 h after exposure to 64 μg/mL (Table 5).
Herbal drugs are often claimed to be nontoxic or low
toxic, but this is not always the case, especially for cer-
tain plant extracts and phytochemicals [32]. It is import-
ant to measure the toxicity of new antimicrobial agents
to cell lines and animals. The in vitro cytotoxicity assay
indicated that EF60 was minimally toxic to HUVEC with
an IC50 of 75 μg/mL. More studies with additional hu-
man cell lines and animals should be done to evaluate
the toxicity of EF60.
Conclusion
In conclusion, EF60, a plant fraction rich in phenan-
threnes, has a potent activity against Gram-positive bac-
teria, including MRSA and S. aureus clinical isolates,
which represents the most frequent cause of complicated
skin and soft tissue infections worldwide [38]. This anti-
microbial activity of EF60 seems to have a direct correl-
ation to the traditional use of the herb for curing skin
cracks and abscesses. Our study revealed that EF60 may
be applied to the development of natural antibacterial
products. However, more studies on the in vivo anti-
microbial activity, bioavailability, and mechanism of ac-
tion of EF60 are needed to be conducted.
Additional file
Additional file 1: Figure S1. HPLC analysis of standard sample and
EF60. Table S1. The retention times of standard samples and
compounds of EF60. Figure S2. UV spectrum of standard samples and
compounds 1–8 of EF60. (DOCX 427 kb)
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